News and Trends 20 Aug 2024
Fighting mpox: promising vaccines to watch
As Bavarian Nordic ramps up production of the only marketed mpox vaccine, a few clinical trials are underway to combat the outbreak.
Infectious disease
- Latest Posts
Best in Biotech 6 Jun 2024
Eight biotech companies advancing the field of siRNA
Explore the growing sector of siRNA and discover eight biotech companies spearheading this innovative field.
In Depth 25 Apr 2024
What are biotech companies doing to tackle malaria?
As we observe World Malaria Day on April 25, let’s take a look at some of the latest progress and new treatments against malaria.
In Depth 4 Apr 2024
Seven diseases CRISPR technology could cure
Here are some of the diseases that scientists aim to tackle using CRISPR technology, testing its possibilities and limits as a medical tool.
News and Trends 21 Dec 2023
The big pharma race against deadly RSV steps up in 2023
GSK and Pfizer received FDA approval for their RSV vaccines in 2023. Now, AstraZeneca has joined the race with its latest acquisition.
Best in Biotech 7 Nov 2023
Eight biotech companies tackling infectious diseases head-on
Infectious diseases are diseases that are caused by pathogens that enter the body, hijack the body’s immune system and multiply, causing an infection. Five of the deadliest infectious diseases are measles, tuberculosis, malaria, diarrhoeal disease and influenza, according to the World Economic Forum. While Our World in Data statistics suggest that there has been almost […]
ADVERTISEMENT
ADVERTISEMENT
In Depth 11 Jul 2023
AIS Biotech: startup employs carbohydrates to fight the flu
Keen on discovering novel ways to tackle viral infections, AIS Biotech, a French company based in the Alps, aims to combat influenza, more commonly known as the flu, by leveraging the medicinal promise behind glycobiotechnology. A field that has been gaining momentum over the past decade, glycobiotechnology is the study of complex carbohydrates which has […]
News and Trends 29 Jun 2023
AI program finds multiple influenza drug targets
Poolbeg Pharma, a clinical-stage biopharma company focusing on infectious and other prevalent diseases, has announced a breakthrough in its world-first influenza Artificial Intelligence (AI) Programme working with the company CytoReason. Poolbeg’s disease progression data from influenza human challenge trials combined with CytoReason’s broad repositories of curated disease data were analyzed using CytoReason’s AI-led platform. The […]
In Depth 26 May 2023
Could new Lyme disease tests help to prevent chronic infection?
Lyme disease is the most common vector-borne disease in the U.S. – a new CDC estimate suggests that approximately 476,000 Americans are diagnosed with Lyme disease each year – and it is caused by the bacterium Borrelia burgdorferi. It is primarily transmitted to humans through the bite of an infected Ixodes tick; also known as […]
In Depth 26 Apr 2023
Vaccine for honeybees: a new hope for American foulbrood disease
In the last few years, there has been an ongoing movement to ‘save the bees’, and the U.S. biotech Dalan Animal Health is playing its part in doing just that, having created a vaccine for honeybees to protect them from the destructive and fatal effects of American foulbrood (AFB). AFB is an infectious bacterial brood […]
In Depth 19 Apr 2023
How Vaccine Platforms Can Prepare Us for Future Pandemics
The COVID-19 pandemic exposed the weaknesses in our defenses. Vaccine platforms will be powerful tools for reacting faster to future pandemics. Multiple COVID-19 vaccines became available across the world to tackle the COVID-19 pandemic, signaling a historic moment for vaccine development due to the speed at which they were created. And with scientists believing that […]
In Depth 14 Apr 2023
mRNA vaccines: a promising future
In 1978, nearly two decades after the discovery of messenger RNA (mRNA), the concept of a vaccine made from mRNA was materialized. Like its name suggests, mRNAs are messengers that aid in decoding genetic information from DNA to synthesize proteins, a key cellular function. Previous attempts at developing a vaccine using mRNA failed because mRNA […]
ADVERTISEMENT